Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: Structural studies on specific CYP2D6 substrate metabolism

Xenobiotica

Volumn 27, Issue 4, 1997, Pages 319-340

  Lewis, D F V ^a   Eddershaw, P J ^b   Goldfarb, P S ^a   Tarbit, M H ^b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BUFURALOL; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DESIPRAMINE; DEXTROMETHORPHAN; METOPROLOL; PERHEXILINE; QUINIDINE; SELEGILINE; SPARTEINE; TAMOXIFEN; TROPISETRON;

ARTICLE; DRUG METABOLISM; ENZYME SUBSTRATE; GENETIC POLYMORPHISM; HUMAN; MOLECULAR MODEL; MUTAGENESIS; NONHUMAN;

BACTERIA (MICROORGANISMS);

EID: 0030914738     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982597240497     Document Type: Article

References (66)

1. ACKLAND, M. J., 1993, Correlation between site specificity and electrophilic frontier values in the metabolic hydroxylation of aromatic substrates: a molecular modelling study. Xenobiotica, 23, 1135-1144.
2. AYALOGU, E. O., SNELLING, J., LEWIS, D. F. V., TALWAR, S., CLIFFORD, M. N. and IOANNIDES, C., 1995, Selective induction of hepatic CYP1A2 by the oral administration of caffeine to rats. Biochimica et Biophysica Acta, 1272, 89-94.
3. BOOBIS, A. R., SESARDIC, D., MURRAY, B. P., EDWARDS, R. J., SINGLETON, A. M., RICH, K. J., MURRAY, S., DE LA TORRE, R., SEGURA, J., PELKONEN, O., PASANEN, M., KOBAYASHI, S., ZHI-GUANG, T. and DAVIES, D. S., 1990, Species variation in the response of the cytochrome P-450-dependent monoxygenase system to inducers and inhibitors. Xenobiotica, 20, 1139-1161.
4. BOYD, G. W., COOMBS, M. M., IONNIDES, C., LEWIS, D. F. V., SNELLING and TSAKALOF, A., 1995, Species variation in the metabolism of 15,16-dihydro-11-methylcyclopenta[a]phenanthren-17-one to its 3,4-dihydrodiol, the proximate carcinogen. Carcinogenesis, 16, 2351-2355.
5. COHCORAN, O. M., HYLAND, R., JONES, B. C. and SMITH, D. A., 1994, Species differences in the in vitro metabolism of probe substrates for the CYP2 enzymes. In Cytochrome P450 : Proceedings of the 8th International Conference, edited by M. C. Lechner (Paris: Libbey), pp. 761-764.
6. CRESPI, C. L., PENMAN, B. W., GELBOIN, H. V. and GONZALEZ, F. J., 1991, A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis, 12, 1197-1201.
7. CRESPI, C. L., STEIMEL, D. T., PENMAN, B. W., KORZEKWA, K. R., FERNANDEZ-SALGUERO, P., BUTERS, J. T. M., GELBOIN, H. V., GONZALEZ, F. J., IDLE, J. R. and DALY, A. K., 1995, Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. In Proceedings of the 4th International ISSX Meeting, Seattle, Washington, 27-31 August, 1995, p. 54.
8. CRIBB, A., NUSS, C. and WANG, R., 1995, Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6. Drug Metabolism and Disposition, 23, 671-675.
9. DAYER, P., LEEMAN, T. and STRIBERNI, R., 1989, Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P450db, activity. Clinical Pharmacology and Therapeutics, 45, 34-40.
10. DE GROOT, M. J., BULOO, G. J., HANSEN, K. T. and VERMEULEN, N. P. E., 1995, Computer prediction and experimental validation of cytochrome P4502D6-dependent oxidation of GBR 12909, Drug Metabolism and Disposition, 23, 667-669.
11. DEGTYARENKO, K. N. and ARCHAKOV, A. I., 1993, Molecular evolution of P450 superfamily and P450-containing monooxygenase systems. FEBS Letters, 332, 1-8.
12. DIXON, C. M., COLTHUP, P. V., SERABJIT-SINGH, C. J., KERR, B. M., BOEHLERT, C. C., PARK, G. R. and TARBIT, M. H., 1995, Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metabolism and Disposition, 23, 1225-1230.
13. EICHELBAUM, M. and GROSS, A. S., 1990, The genetic polymorphism of debrisoquine/sparteine metabolism in clinical aspects. Pharmacology and Therapeutics, 46, 377-394.
14. EICHELBAUM, M., REETZ, K.-P., SCHMIDT, E. K. and ZEKORN, C., 1986, The genetic polymorphism of sparteine metabolism. Xenobiotica, 16, 465-481.
15. ELLIS, S. W., CHING, M. S., WATSON, P. F., HENDERSON, C. J., SIMULA, A. P., LENNARD, M. S., TUCKER, G. T. and WOODS, H. F., 1992, Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Biochemical Pharmacology, 44, 617-620.
16. ELLIS, W., SIMULA, A., HARLOW, J., HAYHURST, G., SMITH, G., LENNARD, M., TUCKER, G. and WOLF, C. R., 1994, A role for Asp-301 in cytochrome P4502D6 catalysis. In 10th International Symposium on Microsomes and Drug Oxidations, Toronto, Canada, p. 427.
17. ELLIS, S. W., ROWLAND, K., ACKLAND, M. J., REKKA, E., SIMULA, A. P., LENNARD, M. S., WOLF, C. R. and TUCKER, G. T., 1996, Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol. Biochemical Journal, 316, 647-654.
18. FISCHER, V., VICKERS, A. E. M., HEITZ, F., MAHADEVAN, S., BALDECK, J.-P., MINERY, P. and TYNES, R., 1994, The polymorphic cytochrome P-450 2D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metabolism and Disposition, 22, 269-274.
19. FUNAE, Y. and IMAOKA, S., 1993, Cytochrome P450 in rodents. In Cytochrome P450, edited by J. B. Schenkman and H. Griem (Berlin: Springer), pp. 221-238.
20. GONZALEZ, F. J. and GELBOIN, H. V., 1994, Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metabolism Reviews, 26, 165-183.
21. GONZALEZ, F. J., SKODA, R. C., KIMURA, S., UMENO, M., ZANGER, U. M., NEBERT, D. W., GELBOIN, H. V., HARDWICK, J. P. and MEYER, U. A., 1988a, Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature, 331, 442-446.
22. GONZALEZ, F. J., VILBOIS, F., HARDWICK, J. P., MCBRIDE, O. W., NEBERT, D. W., GELBOIN, H. V. and MEYER, U. A., 1988b, Human debrisoquine 4-hydroxylase (P450IIDI): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics, 2, 174-179.
23. GOTOH, O., 1992, Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. Journal of Biological Chemistry, 267, 83-90.
24. GRACE, J. M., KINTER, M. T. and MACDONALD, T. L., 1994, Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,α-dimethyl-propynylphenethylamine, by cytochrome P450 2D6. Chemical Research in Toxicology, 7, 286-290.
25. GRAHAM-LORENCE, S. and PETERSON, J. A., 1996, P450s: structural similarities and functional differences, FASEB Journal, 10, 206-214.
26. GRAHAM-LORENCE, S., SANDERS, D. and PETERSON, J. A., 1994, Characterization of mutants in the P450 domain of P450BM3. In Proceedings of the 10th International Symposium on Microsomes and Drug Oxidations, Toronto, Canada, 18-21 July, 1994, p. 435.
27. HASEMANN, C. A., KURUMBAIL, R. G., BODDUPALLI, S. S., PETERSON, J. A. and DEISENHOFER, J., 1995, Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure, 3, 41-62.
28. HEIM, M. and MEYER, V. A., 1990, Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet, 336, 529-532.
29. ISLAM, S. A., WOLF, C. R., LENNARD, M. S. and STERNBERG, M. J. E., 1991, A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis, 12, 2211-2219.
30. KORZEKWA, K. R. and JONES, J. P., 1993, Predicting the cytochrome P450 mediated metabolism of xenobiotics. Pharmacogenetics, 3, 1-18.
31. KOYMANS, L., VERMEULEN, N. P. E., VAN ACKER, S. A. B. E., TE KOPPELE, J. M., HEYKANTS, J. J. P., LAVRIJSEN, K., MEULDERMANS, W. and DONNÉ-OP DEN KELDER, G. M., 1992, A predictive model for substrates of cytochrome P-450-debrisoquine (2D6). Chemical Research in Toxicology, 5, 211-219.
32. KOYMANS, L. M. H., VERMEULEN, N. P. E., BAARSLAG, A. and DONNE-OP DEN KELDER, G. M., 1993, A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. Journal of Computer-Aided Molecular Design, 7, 281-289.
33. LAKE, B. G. and LEWIS, D. F. V., 1996, The CYP4 family. In Cytochromes P450: Metabolic and Toxicological Aspects, edited by C. Ioannides (Boca Raton: CRC Press), pp. 269-295.
34. LENNARD, M. S., TUCKER, G. T., SILAS, J. H. and WOODS, H. F., 1986, Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica, 16, 435-447.
35. bm3). Xenobiotica, 25, 333-366.
36. LEWIS, D. F. V. 1995b, The cytochromes P450: ubiquitous enzymes of metabolism. Manufacturing Chemist, 66, 35-37.
37. LEWIS, D. F. V., 1996a, Cytochromes P450: Structure, Function and Mechanism (London: Taylor & Francis).
38. LEWIS, D. F. V., 1996b, Molecular modelling of mammalian cytochromes P450 with specific substrates and inhibitors. In Cytochromes P450 : Metabolic and Toxicological Aspects, edited by C. Ioannides (Boca Raton: CRC Press), pp. 353-389.
39. LEWIS, D. F. V. and LAKE, B. G., 1995, Molecular modelling of members of the CYP2A subfamily: application to studies of enzyme specificity. Xenobiotica, 25, 585-598.
40. LEWIS, D. F. V. and LAKE, B. G., 1996, Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYPlA substrate specificity in terms of active site amino acid residues. Xenobiotica, 26, 723-753.
41. LEWIS, D. F. V., LAKE, B. G. and PARKE, D. V., 1995, Molecular orbital-generated QSARs in an homologous series of alkoxy resorufins and studies of their interactive docking with cytochromes P450. Xenobiotica, 25, 1355-1369.
42. LEWIS, D. F. V., EDDERSHAW, P. J., GOLDFARB, P. S. and TARBIT, M. H., 1996, Molecular modelling of CYP3A4 from an alignment with CYP102: Identification of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica, 26, 1067-1086.
43. coh substrate specificity by mutation of a single amino-acid residue. Nature 339, 632-634.
44. MAREZ, D., SABBAGH, N., LEGRAND, M., LO, J. M., GUDDICHI, G. M., BOONE, P. and BROLY, F., 1995, A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics, 5, 305-311.
45. MATSUNAGA, E., ZEUGIN, T., ZANGER, U. M., AOYAMA, T., MEYER, U. A. and GONZALEZ, F. J., 1990, Sequence requirements for cytochrome P-450IID1 catalytic activity. Journal of Biological Chemistry, 265, 17197-17201.
46. MEYER, U. A., 1991, Molecular mechanisms causing genetic polymorphisms of drug metabolizing enzymes. Frontiers in Biotransformation, 9, 215-245.
47. MEYER, V. A., GUT, J., KRONBACH, T., SKODA, C., MEIER, U. T., CATIN, T. and DAYER, P., 1986, The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica, 16, 449-464.
48. MIKUS, G., KROEMER, N. K. and EICHELBAUM, M., 1994, Clinical implications of genetic polymorphisms in human drug metabolism. Frontiers in Biotransformation, 9, 215-245.
49. MODI, S., PRIMROSE, W. U., BOYLE, J., GIBSON, C. F., LIAN, L.-Y. and ROBERTS, G. C. K., 1995, NMR studies of substrate binding to cytochrome P450BM3: comparisons to cytochrome P450cam. Biochemistry, 34, 8982-8988.
50. 4502D6 based on homology modeling and NMR studies of substrate binding. Biochemistry, 35, 4540-4550.
51. NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN, J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., ESTABROOK, R. W., GUNSALUS, I. C. and NEBERT, D. W., 1996, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1-42.
52. OTTON, S. V., CREWE, H. K., LENNARD, M. S., TUCKER, G. T. and WOODS, H. F., 1988, Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 247, 242-247.
53. PAINE, A. J., 1991, The cytochrome P450 gene superfamily. International Journal of Experimental Pathology, 72, 349-363.
54. PENMAN, B. W., REECE, J., SMITH, T., YANG, C. S., GELBOIN, H. V., GONZALEZ, F. J. and CRESPI, C. L., 1993, Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics, 3, 28-39.
55. PRICE-EVANS, D. A., 1993, Genetic Factors in Drug Therapy (Cambridge: Cambridge University Press).
56. RAVICHANDRAN, K. G., BODDUPALLI, S., HASEMANN, C. A., PETERSON, J. A. and DIESENHOFER, J., 1993, Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450s. Science, 261, 731-736.
57. RAUNIO, H. and PELKONEN, O., 1995, Cancer genetics: Genetic factors in the activation and inactivation of chemical carcinogens. In Drugs, Diet and Disease, vol. 1. Mechanistic Approaches to Cancer, edited by C. Ioannides and D. F. V. Lewis (Chichester: Ellis Horwood), pp. 229-258.
58. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
59. SMITH, D. A. and JONES, B. C., 1992, Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochemical Pharmacology, 44, 2089-2098.
60. SMITH, D. A., ABEL, S. M., HYLAND, R. and JONES, B. C., 1997, Cytochrome P450s: selectivity and measurement in vivo. Xenobiotica, (in press).
61. STROBL, G. R., VON KRUEDENER, S., STOCKIGT, J., GUENGERICH, F. P. and WOLFF, T., 1993, Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: Molecular modelling and inhibition studies. Journal of Medicinal Chemistry, 36, 1136-1145.
62. SZKLARZ, G. D., HE, Y. A. and HALPERT, J. R., 1995, Site-directed mutagenesis as a tool for molecular modelling of cytochrome P4502B1, Biochemistry, 34, 14312-14322.
63. TYNDALE, R., AOYAMA, T., BROLY, F., MATSUNAGA, T., INABA, T., KALOW, W., GELBOIN, H. V., MEYER, U. A. and GONZALEZ, F. J., 1991, Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281 : possible association with the poor metabolizer phenotype. Pharmacogenetics, 1, 26-32.
64. 14C] tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochemical Pharmacology, 49, 1035-1042.
65. WISEMAN, H. and LEWIS, D. F. V., 1996, The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling studies of the enzyme-substrate interactions. Carcinogenesis, 17, 1357-1360.
66. WOLFF, T., DISTLERATH, L. M., WORTHINGTON, M. T., GROOPMAN, J. D., HAMMONS, G. J., KADLUBAR, F. F., PROUGH, R. A., MARTIN, M. V. and GUENGERICH, F. P., 1985, Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modelling. Cancer Research, 45, 2116-2122.